Circassia Group PLC banner

Circassia Group PLC
LSE:CIR

Watchlist Manager
Circassia Group PLC Logo
Circassia Group PLC
LSE:CIR
Watchlist
Price: 36.5 GBX 0.83% Market Closed
Market Cap: £152.7m

Circassia Group PLC
Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Circassia Group PLC
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Circassia Group PLC
LSE:CIR
Common Stock
£300k
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Common Stock
$894k
CAGR 3-Years
31%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Common Stock
£137k
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Compass Pathways PLC
NASDAQ:CMPS
Common Stock
$973k
CAGR 3-Years
25%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Common Stock
£6.7m
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
1%
Oxford BioMedica PLC
LSE:OXB
Common Stock
£60.4m
CAGR 3-Years
8%
CAGR 5-Years
8%
CAGR 10-Years
9%
No Stocks Found

Circassia Group PLC
Glance View

Market Cap
152.7m GBX
Industry
Biotechnology

Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. The company is headquartered in Oxford, Oxfordshire and currently employs 128 full-time employees. The company went IPO on 2014-03-13. The firm operates through two segments: NIOX and COPD. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). The COPD segment relates to the Tudorza and Duaklir Pressair products marketed in the United States, where they are indicated for the maintenance treatment of patients with COPD. Its NIOX FeNO measurement and monitoring products are used by physicians around the world to help improve asthma diagnosis and management. Its FeNO diagnosis and management products helps healthcare to professionals manage their patient's asthma. Its NIOX VERO is a non-invasive, point-of-care system that provides FeNO measurements. The firm provides products and services in around 50 countries.

CIR Intrinsic Value
Not Available

See Also

What is Circassia Group PLC's Common Stock?
Common Stock
300k GBP

Based on the financial report for Dec 31, 2022, Circassia Group PLC's Common Stock amounts to 300k GBP.

What is Circassia Group PLC's Common Stock growth rate?
Common Stock CAGR 5Y
0%

Over the last year, the Common Stock growth was 0%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett